Stockscreener 앱 받기
1,183.17
1.79%
-25.83
Lilly Eli Co 주식(LLY)의 최신 뉴스
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? - The Motley Fool
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Boone County residents denied hearing on possible Eli Lilly pollutants - reporter.net
Berenberg Bank Initiates Eli Lilly and Co(LLY.US) With Hold Rating, Announces Target Price $1,220 - Moomoo
Kirkland & Ellis Helps Eli Lilly Sue to Shut Down Alleged Black Market for GLP 1 - Law.com
Lilly Claims 6 Vendors Illegally Sold Obesity Drug Candidate - Law360
Eli Lilly and Company (NYSE:LLY) Stays Tied To The Metabolic Health Story - Kalkine Media
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race - Yahoo! Finance Canada
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity - AOL.com
Eli Lilly targets booming black market for retatrutide - STAT
Novo CEO says obesity market won't be winner-take-all battle with Lilly - Reuters
Eli Lilly Stock (LLY) Opinions on Q2 Earnings Results - Quiver Quantitative
Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope - TechStock²
Lilly veteran named director of IU Kelley School’s life sciences center - Indianapolis Business Journal
Lilly Filed Six Lawsuits Against 14,000 Listings. The Real Target Is the Payment Layer - Business Model Analyst
Lilly gains access to market that could add millions of customers - thestreet.com
Eli Lilly is a great company. Is it still a great stock? - Investing.com
Eli Lilly is a great company. Is it still a great stock? By Investing.com - Investing.com Canada
Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits - Pharmaceutical Technology
Lilly Takes On Peptide Industry to Protect Buzzy Obesity Shot Retatrutide - Bloomberg
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - Reuters
Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales - RTTNews
Is Eli Lilly (NYSE:LLY) Drawing Fresh Attention As Incretin Therapies Advance? - Kalkine Media
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly By Investing.com - Investing.com India
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly - Investing.com
Understanding Attorney General v. Eli Lilly & Co.: What Regulated Businesses Should Know About Potentially Expanded MCPA Exposure - JD Supra
Eli Lilly Sues Six Firms Over Black-Market Sales of Unapproved Weight-Loss Drug - finance.biggo.com
What Is Keeping Eli Lilly (NYSE:LLY) in View as Inflation Data Nears? - Kalkine Media
‘Entirely Unverified Retatrutide’ Being Sold on Black Market: Lilly Sues 6 US Companies - Health and Me
Eli Lilly Stock Falls While Retatrutide Lawsuits Expand - TradingView
Lilly Targets Black-Market Retatrutide Sellers - TradingView
Eli Lilly sues six companies for selling illegal versions of groundbreaking weight-loss drug - Straight Arrow
Veeva Systems (VEEV) Expands AI CRM Role With Eli Lilly Win Is Its Moat Deepening? - simplywall.st
Eli Lilly files first lawsuits over retatrutide ‘black market’ - Endpoints News
Lilly escalates fight over weight-loss shots sold on black market - Indianapolis Business Journal
Eli Lilly Goes After Sellers of Its Unapproved Drug - Newser
Eli Lilly targets alleged black market sales of its experimental GLP-1 drug - The Hill
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade) (LLY) - Seeking Alpha
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas - Fierce Pharma
Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities - Benzinga
Lilly escalates its fight against black market weight-loss shots - Fortune
Lilly Escalates Its Fight Against Black Market Weight-Loss Shots - Bloomberg
Lilly Escalates Fight Against Black Market Weight-Loss Shots (3) - Bloomberg Law News
Eli Lilly Sues 6 US Sellers Over Black-Market Retatrutide, Calls Products ‘Unverified’ - outlookbusiness.com
InduPro's 'protein neighbourhoods' draw Sanofi, Lilly backing after earlier deals - firstwordpharma.com
Lilly sues six U.S. companies for allegedly selling black-market retatrutide - PharmaLive
Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup - ChartMill
Lilly cracks down on retatrutide black marketeers - firstwordpharma.com
Eli Lilly Steps Up Retatrutide Crackdown With Six New Lawsuits – CMO Hyman Says Drug Sold In Black Market Is ‘Not A Medicine’ - Yahoo Finance
Black-Market GLP-1s: Eli Lilly Sues Six Sellers Of Experimental Obesity Drugs - ndtvprofit.com
Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs - WSJ
Eli Lilly Sues Six US Companies Over Illegal Retatrutide Sales - Межа. Новини України.
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug - qz.com
Tema ETFs LLC Has $29.99 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly escalates fight against black market weight-loss medicines - BusinessLine
Berenberg cuts Novo Nordisk as Lilly’s obesity dominance limits upside By Investing.com - Investing.com Australia
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market - PR Newswire
Eli Lilly official, others explain what brought their companies to Alabama - Decatur Daily
Better Buy: Eli Lilly vs. Novo Nordisk - fool.com
Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Down 1.5% After Insider Selling - MarketBeat
Eli Lilly's Weight-Loss Pill Wins U.K. Approval - Briefs Finance
Why Is Eli Lilly (NYSE:LLY) the Healthcare Name in Focus After Its Obesity Pill Nod? - Kalkine Media
Eli Lilly Scores Major Win in Weight-Loss Drug Race - Yahoo Finance
Eli Lilly Just Made a Huge Bet on Psychedelics for Mental Health - Flow Space
0.47%
0.62%
자본화:
|
볼륨(24시간):